Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Zentiva","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra to Commercialize Myring In France, Poland And UK","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CZECH REPUBLIC","productType":"Peptide","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Adalvo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"CZECH REPUBLIC","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Tillomed Laboratories Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Completes Major Product Acquisition from Tillomed Spain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CZECH REPUBLIC","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Zentiva","sponsor":"Mabxience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys\u00ae (Bevacizumab) in 21 Countries Across Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Will Be the First Offering EU Dossier for Finasteride \/ Tadalafil 5 Mg \/ 5 Mg Fixed-Dose Combination","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal BE Trial on Sacubitril + Valsartan Development","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U announces Completion of Bioequivalence Trials on Sertraline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Convenient Treatment Option for Thromboembolic Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Zentiva","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CZECH REPUBLIC","productType":"Peptide","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Prague Scientific

    Menu

    Prague Scientific

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Zentiva

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK

              Details:

              Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

              Lead Product(s): Liraglutide

              Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic

              Highest Development Status: Approved Product Type: Peptide

              Recipient: Biocon

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 28, 2024

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Zentiva

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology

              Details:

              Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Adalvo

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration January 09, 2023

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Zentiva

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zentiva Completes Major Product Acquisition from Tillomed Spain

              Details:

              Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Tillomed Laboratories Ltd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 16, 2022

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Zentiva

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe

              Details:

              Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.

              Lead Product(s): Liraglutide

              Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic

              Highest Development Status: Undisclosed Product Type: Peptide

              Recipient: Biocon

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 23, 2022

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Zentiva

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys® (Bevacizumab) in 21 Countries Across Europe

              Details:

              Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.

              Lead Product(s): Bevacizumab-maly,Fluorouracil,Calcium Folinate

              Therapeutic Area: Oncology Product Name: Alymsys

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Mabxience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 09, 2021

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Zentiva

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mithra to Commercialize Myring In France, Poland And UK

              Details:

              Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.

              Lead Product(s): Etonogestrel,Ethinyl Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Myring

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Mithra Pharmaceuticals

              Deal Size: $2.2 million Upfront Cash: Undisclosed

              Deal Type: Agreement July 06, 2020

              Zentiva Company banner

              Chinaplas 2024

              Not Confirmed

              envelop Contact Supplier

              Prague Scientific

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              A Convenient Treatment Option for Thromboembolic Events

              Details:

              Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.

              Lead Product(s): Rivaroxaban

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rivaroxaban-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Prague Scientific

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules

              Details:

              Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid.

              Lead Product(s): Omeprazole Magnesium

              Therapeutic Area: Gastroenterology Product Name: Omeprazole Magnesium-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Prague Scientific

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zent2U Will Be the First Offering EU Dossier for Finasteride / Tadalafil 5 Mg / 5 Mg Fixed-Dose Combination

              Details:

              Finasteride and tadalafil combination is used to treat men with benign prostatic hyperplasia (BPH). Tadalafil is a PDE5 inhibitor and finasteride blocks the action of 5-alpha-reductase which will increase testosterone levels in the body, which decreases prostate size.

              Lead Product(s): Finasteride,Tadalafil

              Therapeutic Area: Urology Product Name: Finasteride/Tadalafil-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Prague Scientific

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development

              Details:

              Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.

              Lead Product(s): Sitagliptin Phosphate

              Therapeutic Area: Endocrinology Product Name: Sitagliptin-Generic

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY